Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Acute encephalopathy after postoperative nivolumab therapy for esophageal cancer:posterior reversible encephalopathy syndrome versus immune-related encephalitis.

Created on 12 Nov 2026

Authors

Byonggu An, Tetsuya Abe, Yasumitsu Oe, Atsushi Tsuji, Yoshio Sakaue, Toru Imagami, Nobuyuki Takao, Akira Sogawa, Takashi Matsunaga, Akiyoshi Mizumoto, Toru Miyake, Takeshi Togawa

Published in

The journal of medical investigation : JMI. Volume 73. Issue 3.4. Pages 552-557.

Abstract

Neurological immune-related adverse events associated with nivolumab are rare but may pose a diagnostic challenge in postoperative patients, particularly in distinguishing posterior reversible encephalopathy syndrome (PRES) from immune-related encephalitis.
A patient who had undergone surgery for esophageal cancer received adjuvant nivolumab therapy and subsequently required emergency surgery for postoperative adhesive small bowel obstruction. Seven hours after surgery, acute disturbance of consciousness developed in the setting of marked hypertension. Brain magnetic resonance imaging (MRI) revealed scattered hyperintense lesions on T2-weighted fluid-attenuated inversion recovery (FLAIR) images that were not strictly posterior-dominant. Given the diagnostic uncertainty between atypical PRES and immune-related encephalitis, a combined therapeutic approach consisting of blood pressure control and systemic corticosteroid therapy was initiated. No further neurological events occurred, and follow-up imaging demonstrated near-complete resolution of the lesions.
This case highlights the diagnostic challenge of acute encephalopathy in postoperative patients treated with immune checkpoint inhibitors. Because PRES and immune-related encephalitis may present with overlapping clinical and radiological features, early neuroimaging and a tailored therapeutic approach, including both blood pressure control and immunosuppressive therapy, are essential for appropriate management. J. Med. Invest. 73 : 552-557, August, 2026.

PMID:
43014793
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement